CHECKPOINT THERAPEUTICS INC (CKPT) Fundamental Analysis & Valuation

NASDAQ:CKPT • US1628282063

4.26 USD
+0.03 (+0.71%)
At close: May 29, 2025
4.2705 USD
+0.01 (+0.25%)
After Hours: 5/29/2025, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CKPT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, CKPT scores 1 out of 10 in our fundamental rating. CKPT was compared to 520 industry peers in the Biotechnology industry. CKPT has a bad profitability rating. Also its financial health evaluation is rather negative. CKPT has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

0

1. CKPT Profitability Analysis

1.1 Basic Checks

  • In the past year CKPT has reported negative net income.
  • CKPT had a negative operating cash flow in the past year.
  • CKPT had negative earnings in each of the past 5 years.
  • In the past 5 years CKPT always reported negative operating cash flow.
CKPT Yearly Net Income VS EBIT VS OCF VS FCFCKPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • CKPT has a Return On Assets of -752.78%. This is amonst the worse of the industry: CKPT underperforms 97.67% of its industry peers.
Industry RankSector Rank
ROA -752.78%
ROE N/A
ROIC N/A
ROA(3y)-729.34%
ROA(5y)-468.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CKPT Yearly ROA, ROE, ROICCKPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500

1.3 Margins

  • CKPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CKPT Yearly Profit, Operating, Gross MarginsCKPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. CKPT Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CKPT has been increased compared to 1 year ago.
  • CKPT has more shares outstanding than it did 5 years ago.
  • CKPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CKPT Yearly Shares OutstandingCKPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CKPT Yearly Total Debt VS Total AssetsCKPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • CKPT has an Altman-Z score of -85.21. This is a bad value and indicates that CKPT is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -85.21, CKPT is doing worse than 96.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -85.21
ROIC/WACCN/A
WACCN/A
CKPT Yearly LT Debt VS Equity VS FCFCKPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

  • A Current Ratio of 0.37 indicates that CKPT may have some problems paying its short term obligations.
  • CKPT has a worse Current ratio (0.37) than 93.74% of its industry peers.
  • CKPT has a Quick Ratio of 0.37. This is a bad value and indicates that CKPT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.37, CKPT is not doing good in the industry: 93.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.37
CKPT Yearly Current Assets VS Current LiabilitesCKPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CKPT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 53.43% over the past year.
  • Looking at the last year, CKPT shows a very negative growth in Revenue. The Revenue has decreased by -60.19% in the last year.
  • Measured over the past years, CKPT shows a very negative growth in Revenue. The Revenue has been decreasing by -52.58% on average per year.
EPS 1Y (TTM)53.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.42%
Revenue 1Y (TTM)-60.19%
Revenue growth 3Y-46.65%
Revenue growth 5Y-52.58%
Sales Q2Q%N/A

3.2 Future

  • CKPT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.84% yearly.
  • Based on estimates for the next years, CKPT will show a very strong growth in Revenue. The Revenue will grow by 711.65% on average per year.
EPS Next Y87.52%
EPS Next 2Y67.51%
EPS Next 3Y85.74%
EPS Next 5Y31.84%
Revenue Next Year300659%
Revenue Next 2Y11555.7%
Revenue Next 3Y3960.1%
Revenue Next 5Y711.65%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CKPT Yearly Revenue VS EstimatesCKPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CKPT Yearly EPS VS EstimatesCKPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

4

4. CKPT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CKPT. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 3.70, which indicates a rather cheap valuation of CKPT.
  • 98.57% of the companies in the same industry are more expensive than CKPT, based on the Price/Forward Earnings ratio.
  • CKPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 3.7
CKPT Price Earnings VS Forward Price EarningsCKPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CKPT Per share dataCKPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CKPT's earnings are expected to grow with 85.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.51%
EPS Next 3Y85.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CKPT Dividend Analysis

5.1 Amount

  • No dividends for CKPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CKPT Fundamentals: All Metrics, Ratios and Statistics

CHECKPOINT THERAPEUTICS INC

NASDAQ:CKPT (5/29/2025, 8:00:00 PM)

After market: 4.2705 +0.01 (+0.25%)

4.26

+0.03 (+0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13
Earnings (Next)08-11
Inst Owners37.08%
Inst Owner Change-57.05%
Ins Owners0.2%
Ins Owner Change0%
Market Cap370.71M
Revenue(TTM)41.00K
Net Income(TTM)-56.24M
Analysts77.78
Price Target4.42 (3.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-154.89%
Min EPS beat(2)-256.04%
Max EPS beat(2)-53.74%
EPS beat(4)1
Avg EPS beat(4)-71.5%
Min EPS beat(4)-256.04%
Max EPS beat(4)42.14%
EPS beat(8)3
Avg EPS beat(8)-41.96%
EPS beat(12)5
Avg EPS beat(12)-34.73%
EPS beat(16)6
Avg EPS beat(16)-35.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-63.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.7
P/S 9041.59
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)1.15
Fwd EY27.06%
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0
BVpS-0.15
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -752.78%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-729.34%
ROA(5y)-468.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.37
Altman-Z -85.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.42%
EPS Next Y87.52%
EPS Next 2Y67.51%
EPS Next 3Y85.74%
EPS Next 5Y31.84%
Revenue 1Y (TTM)-60.19%
Revenue growth 3Y-46.65%
Revenue growth 5Y-52.58%
Sales Q2Q%N/A
Revenue Next Year300659%
Revenue Next 2Y11555.7%
Revenue Next 3Y3960.1%
Revenue Next 5Y711.65%
EBIT growth 1Y-7.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.65%
OCF growth 3YN/A
OCF growth 5YN/A

CHECKPOINT THERAPEUTICS INC / CKPT FAQ

Can you provide the ChartMill fundamental rating for CHECKPOINT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to CKPT.


What is the valuation status for CKPT stock?

ChartMill assigns a valuation rating of 4 / 10 to CHECKPOINT THERAPEUTICS INC (CKPT). This can be considered as Fairly Valued.


How profitable is CHECKPOINT THERAPEUTICS INC (CKPT) stock?

CHECKPOINT THERAPEUTICS INC (CKPT) has a profitability rating of 0 / 10.


How financially healthy is CHECKPOINT THERAPEUTICS INC?

The financial health rating of CHECKPOINT THERAPEUTICS INC (CKPT) is 0 / 10.